The Role Of Telomeres In The Treatment And Detection Of Early AMD (Age Related Macular Degeneration) And Alzheimers Disease

Dr. Tom Dow


  • Rationale of a trial testing TA-65 in AMD.
  • Relative void in treating options for early AMD.
  • Results of our pilot study of TA-65 in early AMD.
Joseph M. Raffaele, M.D.

I have with me today on the Telomere Summit, Dr Tom Dow, who is a Medical and Surgical Ophthalmologist and practiced for over 40 years in Clinical Ophthalmology. He maintains a clinical appointment at the University of Wisconsin, Madison, and is a member of McPherson Eye Research Institute. He has also worked as a physician scientist, conducting clinical trials. Since 2000 he has had a research interest in the role of infection, specifically mycobacteria and paratuberculosis, or MAP, in a broad range of human inflammatory diseases. Also, he has studied clinical applications arising from telomere biology and telomerase, His work testing oral telomerase activator in age-related macular degeneration has led to interest by the National Eye Institute. Welcome, Tom, to the Telomere Summit. And really excited to speak to you. I remember when your study came out in 2016, we had a brief conversation in Las Vegas about it. But I’ve got all sorts of questions, and looking forward to this conversation.

Related Videos

Telomeres & Telomerase Activation; Connecting the Dots

Ron Rothenberg, MD

Telomere Biology And It’s Application To Environmental Toxins And Chronic Inflammatory Disorders

Gordon Crozier, DO

Purchase Now




Login to get access to DrSummits wide selection of expert videos, your summit or video purchases.


Your cart is currently empty.

Return to shop

Sign up


Already have an account? Log In